Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).
Pasi A. Janne
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Clovis; Genentech; Merrimack Pharmaceuticals ; Pfizer; Sanofi
Stock Ownership - GATEKEEPER Pharmaceuticals
Other Remuneration - LabCorp
Suresh S. Ramalingam
Consultant or Advisory Role - AstraZeneca
James Chih-Hsin Yang
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis; InnoPharmax; Lilly; Novartis; Pfizer; Takeda
Honoraria - Abbott Laboratories; AstraZeneca; Bayer; Boehringer Ingelheim; Pfizer; Roche
Research Funding - Boehringer Ingelheim
Myung-Ju Ahn
No relevant relationships to disclose
Dong-Wan Kim
No relevant relationships to disclose
Sang-We Kim
No relevant relationships to disclose
David Planchard
Consultant or Advisory Role - AstraZeneca
Yuichiro Ohe
Honoraria - AstraZeneca
Enriqueta Felip
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Roche
Claire Watkins
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Mireille Cantarini
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Serban Ghiorghiu
Employment or Leadership Position - AstraZeneca (B)
Stock Ownership - AstraZeneca (B)
Malcolm Ranson
Honoraria - AstraZeneca
Research Funding - AstraZeneca